Treatment-resistant depression: what to do when antidepressants haven't worked

There is a particular exhaustion that comes from doing everything right — the appointments, the titration schedules, the six-week waits — and still waking up underneath the same grey ceiling. If that is where you are, this guide was written for you. Not to sell you anything, but to give you the briefing the system never did.

We will define what treatment-resistant depression actually means, why standard antidepressants hit a ceiling, and what the evidence-backed next steps look like — ketamine, Spravato, TMS, and the rest — with honest numbers, real costs, and the questions to ask before you commit to anything. Nothing here is medical advice. It is the map we wish someone had handed us at the start.

What treatment-resistant actually means

The clinical definition is narrower than the lived experience: depression that has not adequately responded to two or more antidepressant trials, each at an adequate dose for an adequate duration — typically six to eight weeks. By that definition, roughly a third of people with major depression qualify.

Read that number again. This is not a rare edge case. The landmark STAR*D trial — the largest real-world antidepressant study ever run — found that each successive medication attempt produced lower remission rates than the one before. By the third and fourth try, remission dropped into the low double digits. The problem was never your effort or your attitude. The problem is a category of drug with a structural ceiling.

"Treatment-resistant" describes the treatments, not you. It means the standard tools have reached their limit — not that you have.

Why antidepressants stop working

Conventional antidepressants work on a maintenance model: modulate serotonin (or norepinephrine, or dopamine) and hope the system downstream reorganizes itself over weeks. For many people that works. For a large minority it does not — and for some it works for a while and then fades, a phenomenon clinicians call tachyphylaxis and patients call "the drug stopped working."

Chronic stress and depression are associated with measurable changes in the brain itself: reduced synaptic connectivity in prefrontal regions, blunted BDNF signalling, entrenched negative prediction loops. Adjusting neurotransmitter levels does not directly address any of that. It is a little like adjusting the thermostat in a house with failing wiring — the setting changes, the infrastructure doesn't.

This is why the most important advances of the last two decades have come from a different direction entirely: treatments that work on the brain's capacity to physically change. Which brings us to the options.

The real options, compared honestly

Below are the six paths with genuine evidence behind them. None is a cure. Each has a profile — speed, format, cost, evidence depth — that makes it right for some people and wrong for others.

For the full financial picture — what each option really costs, what insurance covers, and how HSA/FSA funds, superbills, and prior authorization can cut the out-of-pocket number — read our cost and insurance guide.

How to choose between them

Three questions narrow the field quickly. First: how fast do you need movement? If the situation is severe or urgent, ECT and ketamine-class treatments move in days; TMS and medication strategies move in weeks. Second: what are you willing to experience? Ketamine involves a temporary altered state; TMS involves none at all; that difference alone decides it for many people. Third: what does coverage look like? Spravato and TMS are increasingly reimbursed after failed medication trials; IV ketamine usually is not.

The two options most people land between are ketamine and TMS — we wrote the full head-to-head in Ketamine vs. TMS: two roads into neuroplasticity, and the deep-dive on the faster of the two in our complete ketamine therapy guide and TMS overview.

Whatever you choose, the single strongest predictor of a good outcome is not the molecule or the machine — it is the quality of the provider delivering it. More on that below.

From resistance to neuroplasticity

Here is the reframe most people never get. A brain that has stopped responding to serotonin modulation is not broken — it is stuck. The pattern is entrenched, the connectivity is thinned, and the system has lost the flexibility to update itself. The question worth asking is not "which drug haven't we tried?" but "what restores the capacity to change?"

That capacity has a name: neuroplasticity. We used to think the adult brain was fixed by the mid-twenties. We were wrong — the brain remains plastic across the lifespan, and plasticity can be deliberately increased. Ketamine opens a plastic window within hours. TMS remodels mood circuits over weeks. And the same window is opened, more gently, by sleep, exercise, heat and cold exposure, and focused learning — the full architecture is in The Neuroplasticity Stack.

The goal is not another medication. It is a brain that can update again — and a plan for what to build while the window is open.

This is also why integration matters more than any single session. The treatment opens the door; what you do in the days after determines what moves into the room. We break that down in What is integration therapy?

The NeuroEdge Provider Standard

The gap between an average clinic and an excellent one is enormous, and nowhere does it matter more than in treatment-resistant cases, where hope has already been taxed. Every provider in the NeuroEdge directory is evaluated against seven criteria:

Clinics meeting all seven are listed in our Centers of Excellence. You can browse the full network in Find a Clinic, or by city — for example ketamine and TMS clinics by city.

Frequently asked questions

Sources and further reading

• National Institute of Mental Health — depression
• FDA — Spravato (esketamine) approval for treatment-resistant depression
• STAR*D trial — Rush et al., American Journal of Psychiatry
• JAMA Psychiatry — ketamine and esketamine trial literature
• American Psychiatric Association — TMS clinical guidance
• Mayo Clinic — treatment-resistant depression overview
• NEJM — psilocybin in treatment-resistant depression (COMP360)
• PubMed — neuroplasticity and depression literature

This guide is educational, not medical advice, and does not replace evaluation by a qualified clinician. Treatment-resistant depression is a serious condition; if you are in crisis, contact the 988 Suicide & Crisis Lifeline (call or text 988 in the US) or your local emergency services. Response rates and costs cited reflect published literature and typical market ranges; individual outcomes and pricing vary.